Keywords: taranabant, double, weight, loss, placebo, 52-week, results

Taranabant: double the weight loss of placebo

Article | 07 April 2008

52-week results from two-year Phase III study of Merck & Co's investigational cannabinoid-1 receptor blocker, taranabant, showed patients experienced statistically-significant weight ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Merck

Merck KGaA

Aventis

Aventis Pharma

Sanofi-Aventis

Go to company listing